Publicacions en col·laboració amb investigadors/es de Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (35)

2024

  1. Alcohol Drinking Impacts on Adiposity and Steatotic Liver Disease: Concurrent Effects on Metabolic Pathways and Cardiovascular Risks

    Current Obesity Reports, Vol. 13, Núm. 3, pp. 461-474

  2. Bridging Metabolic-Associated Steatotic Liver Disease and Cardiovascular Risk: A Potential Role for Ketogenesis

    Biomedicines, Vol. 12, Núm. 3

  3. Circulating miR-122-5p, miR-151a-3p, miR-126-5p and miR-21-5p as potential predictive biomarkers for Metabolic Dysfunction-Associated Steatotic Liver Disease assessment

    Journal of Physiology and Biochemistry

  4. Epicardial and liver fat implications in albuminuria: a retrospective study

    Cardiovascular Diabetology, Vol. 23, Núm. 1

  5. FNDC4 reduces hepatocyte inflammatory cell death via AMPKα in metabolic dysfunction-associated steatotic liver disease

    Clinical Nutrition, Vol. 43, Núm. 9, pp. 2221-2233

2023

  1. A new FGF15/19-mediated gut-to-heart axis controls cardiac hypertrophy

    Journal of Pathology, Vol. 261, Núm. 3, pp. 335-348

  2. Antagonic effect of ghrelin and LEAP-2 on hepatic stellate cell activation and liver fibrosis in obesity-associated nonalcoholic fatty liver disease

    European journal of endocrinology, Vol. 188, Núm. 7, pp. 564-577

  3. Comparative effects of glucagon-like peptide-1 receptors agonists, 4-dipeptidyl peptidase inhibitors, and metformin on metabolic syndrome

    Biomedicine and Pharmacotherapy, Vol. 161

  4. Corrigendum: Role of NAFLD on the health related QoL response to lifestyle in patients with metabolic syndrome: The PREDIMED plus cohort(Front. Endocrinol., (2022), 13, (868795), 10.3389/fendo.2022.868795)

    Frontiers in Endocrinology

  5. Dietary Iron, Anemia Markers, Cognition, and Quality of Life in Older Community-Dwelling Subjects at High Cardiovascular Risk

    Nutrients, Vol. 15, Núm. 20

  6. Estimation of fatty liver disease clinical role on glucose metabolic remodelling phenotypes and T2DM onset

    European Journal of Clinical Investigation, Vol. 53, Núm. 10

  7. Isoliquiritigenin in combination with visceral adipose tissue and related markers as a predictive tool for nonalcoholic fatty liver disease

    Journal of Physiology and Biochemistry

  8. Nutritional Interventions with Bacillus coagulans Improved Glucose Metabolism and Hyperinsulinemia in Mice with Acute Intermittent Porphyria

    International Journal of Molecular Sciences, Vol. 24, Núm. 15

  9. Repercussions of absolute and time-rated BMI “yo-yo” fluctuations on cardiovascular stress-related morbidities within the vascular-metabolic CUN cohort

    Frontiers in Endocrinology, Vol. 13

  10. The outcome of boosting mitochondrial activity in alcohol-associated liver disease is organ-dependent

    Hepatology (Baltimore, Md.), Vol. 78, Núm. 3, pp. 878-895

  11. Uroguanylin prevents hepatic steatosis, mitochondrial dysfunction and fibrosis in obesity-associated NAFLD

    Metabolism: Clinical and Experimental, Vol. 147

2022

  1. A nutrigenetic tool for precision dietary management of non-alcoholic fatty liver disease deeming insulin resistance markers

    Panminerva medica, Vol. 64, Núm. 4, pp. 485-496

  2. Diagnostic scores and scales for appraising Nonalcoholic fatty liver disease and omics perspectives for precision medicine

    Current Opinion in Clinical Nutrition and Metabolic Care, Vol. 25, Núm. 5, pp. 285-291

  3. Interactive Role of Surrogate Liver Fibrosis Assessment and Insulin Resistance on the Incidence of Major Cardiovascular Events

    Journal of Clinical Medicine, Vol. 11, Núm. 17

  4. Longitudinal association of dietary acid load with kidney function decline in an older adult population with metabolic syndrome

    Frontiers in Nutrition, Vol. 9